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Abstract
Background We sought to understand the beliefs,
social norms and logistical factors that affect human
papillomavirus (HPV)-positive women’s uptake of
cryotherapy treatment as part of a two-part cervical
cancer screening strategy in rural Kenya.
Methods In-depth interviews within a parent clusterrandomised trial.
Setting Government-run county hospital in western
Kenya.
Participants 273 of 372 (73.4%) HPV-positive women
who underwent cryotherapy
Results Many women feared that an HPV infection meant
they would develop cancer. Almost all women reported
initial fear of the treatment procedure, followed by a more
positive experience than anticipated. Lacking funds for
transportation to the treatment site was the most common
barrier. Women felt that decentralised treatment would be
the most important facilitator of greater access. Spousal
encouragement and financial support were key facilitators
of treatment access, however many women felt that other
husbands in the community would not be supportive.
Women described successfully acquiring treatment as
empowering, and almost all would recommend seeking
cryotherapy to other women who test HPV-positive. Most
felt eager to share their own experiences with others to
encourage treatment.
Conclusions The main facilitators of treatment access
were understanding of the health risks and sense of
empowerment. A decentralised treatment model or
transportation support may facilitate access, along with
improved health messaging about HPV infection, cancer
and the treatment process. Focusing on women’s personal
feelings of empowerment may further improve uptake and
satisfaction. These data will be used to design a strategy
to improve linkage to treatment.
Trial Registration NCT02124252.

Introduction
Cervical cancer, despite being one of the most
preventable cancers through vaccination and
screening, remains the fourth most common
cancer among women worldwide.1 Now rare

Strengths and limitations of the study
►► This study provides insight into women’s experience

obtaining cryotherapy after a receiving positive human papillomavirus test result in western Kenya.
►► The perspectives provided will allow for improved
contextualisation of cervical cancer prevention programmes in similar settings.
►► These qualitative findings are exploratory, and may
not be reflective of larger patterns or associations.
►► Women were interviewed by trained study staff, so
there may have been social desirability bias.
►► We did not interview women who were lost to follow-up, and may therefore have had even more barriers than those identified in this study.

in wealthier countries due to the success of
the cytology-based prevention programme,
cervical cancer continues to be a major public
health issue in low-income and middle-income countries (LMICs). Effective population-based screening, coupled with linkage
to treatment for screen-positive women, is
critical to preventing the development of
cervical cancer. In Kenya, where screening
rates range between 3% and 14%, and vaccination for human papillomavirus (HPV) is
not yet available, cervical cancer is the second
most common cancer in women, and the
leading cause of cancer-related mortality.2
Strategies to address the lack of a screening
programme in LMICs include simpler
screening techniques coupled with cryotherapy for women who screen positive.
Cryotherapy is relatively inexpensive, can
be performed by non-physician providers
and does not require electricity. It has been
promoted along with visual inspection with
acetic acid (VIA) as part of a same day ‘see
& treat’ strategy, although the expense and
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Materials and methods
Study design
We used qualitative data to explore the barriers and facilitators of treatment access for women who tested HPV-positive as part of a two-phase cluster-randomised trial in
rural western Kenya.14 In the first phase, 12 communities
in Migori County were randomised to screening using
self-collected HPV tests either through community health
campaigns in central locations in the villages (CHCs) or
in health facilities. In both the CHC and health facility
arms, education and outreach was led by community
health volunteers, and women who tested HPV-positive
were notified of their results and referred to the Migori
County Hospital for treatment with cryotherapy.15 After
2

treatment, women were invited to participant in an
in-depth interview (IDI) regarding their experience.
The distance between Migori County Hospital and
the 12 study communities ranged from 11 km to 94 km.
Transport around the county was available via motorcycles, public buses and private taxis. In the hospital
compound, treatment was provided by nurses who had
undergone additional training in both cryotherapy and
study procedures prior to study initiation. The medical
superintendent and an experienced nurse facilitator
provided supervision as needed. Women underwent VIA
prior to treatment, followed by cryotherapy, unless the
cervical anatomy was abnormal, the lesion was too large
for the probe or there was suspicion for cancer. In the first
two cases, the woman would be referred for a loop electrosurgical excision procedure (LEEP) within the same
hospital. If there was suspicion for cancer, she was offered
a biopsy and referred for management of cancer. All costs
associated with cryotherapy or LEEP were covered by the
study. Women did not receive compensation for transport
or monetary incentives for participation in the study.
Data sources
IDI guides were developed using selected CFIR constructs
to elicit responses about the client-sided experience and
perceptions of treatment (table 1). Selected constructs
included adaptability, patient needs and resources and
complexity of proposed intervention methods.
IDI guides were developed in English and translated
and conducted in the most common local languages
(Dholuo and Kiswahili) by researchers fluent in those
languages. The first part of the IDIs consisted of closedended questions about sociodemographic characteristics, sexual behaviour, gynaecological history, HIV status,
cervical cancer screening and HPV. Interviewers entered
these data directly into Open Data Kit installed onto study
tablets. The second part of the interviews consisted of
open-ended questions that probed women on what they
understood about HPV and treatment for HPV, their feelings and experience with treatment, barriers and facilitators to treatment, stigma and desire for privacy, and male
and community leader roles in facilitating cervical cancer
prevention. Interviews lasted between 15 min and 25 min.
These data were recorded on the tablets, and then transcribed and translated. All translations were reviewed with
the audio by the study coordinator for accuracy.
Data analysis
Using thematic analysis, one member of the research
team created the codebook using both the IDI guide for
structure and four sample interviews to identify additional
themes that together facilitated a more nuanced interpretation of the data .16 The codebook was then reviewed
and revised by the entire team, followed by a round in
which all four researchers sample coded 10 interviews
to test and revise the codebook. All analysis and codebook development was done using NVivo V.11 software
(QSR International, London, UK). The team then met
Huchko M, et al. BMJ Open 2019;9:e028669. doi:10.1136/bmjopen-2018-028669
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logistical challenges of maintaining supplies, space and
personnel for cryotherapy in remote settings make singlevisit strategies impossible in most settings.3 4
Another simple screening technique is low-cost HPV
testing.5 6 The WHO incorporated the growing body of
evidence supporting HPV testing into recommendations
for a screening programme in low resource settings.7
The current guidelines include HPV primary screening
as the preferred modality, followed by cryotherapy. As
HPV testing has become more widely available and the
evidence for its use more convincing, the programme is
starting to move from ‘see & treat’ to ‘screen & treat,’
referring women for treatment based on a positive HPV
result. While this may be more effective at decreasing
cervical precancer and cancer, there are no currently
available HPV tests that allow for same-visit results. Therefore, the programme must take into consideration how
to deliver HPV test results and counselling in a way that
fosters understanding and facilitates women’s uptake
of the appropriate follow-up. An effective HPV-based
screening programme must take into account the multitude of sociocultural factors such as stigma, fear and
misperceptions, along with the logistical and health
systems factors that affect a woman’s decision-making
and ability to seek screening, understand her results and
obtain treatment if needed.
While multiple studies have evaluated effective
screening methods for women in western Kenya, there
remains a gap in understanding effective strategies to
link women who screen positive for HPV to appropriate
follow-up and treatment.8–12 Given that HPV-based strategies are relatively new to LMICs, there are very little qualitative data exploring women’s experience with treatment.
Understanding the knowledge, beliefs, social norms and
logistical factors that affect women’s decision and ability
to seek treatment is essential in the design of effective
context-specific treatment strategies. We used the Consolidated Framework for Implementation Research (CFIR)
to explore the contextual factors that may have facilitated
HPV-positive women’s access to appropriate treatment
within a community-based screening programme.13
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Construct

Topics covered

Key findings

Intervention characteristics
Relative advantage

►►

Adaptability

►►

Complexity

►►

What are the advantages of the
proposed treatment model?

►► Offered free of charge, outpatient

What are other models of treatment
►► Decentralised treatment or transportation
that would facilitate increased access?
support would improve the model
►► What are factors of the current
treatment model that could be improved?
Perceptions of treatment feasibility and ►► Women had unanswered questions after
sustainability
treatment regarding follow-up, need for
medication or potential impact on fertility
►► What is the participant’s understanding
of the screening and treatment cascade?

Outer setting
Patient needs and resources

►►

What can the health facilities do to
facilitate patient treatment acquisition?
 

►► Provider respect was high

What is the level and impact of male
support?
►► How could community leader
involvement facilitate treatment?

►► Male financial and moral support were

Inner setting
Culture

►►

important to treatment acquisition

►► Many were concerned about post-treatment

abstinence or re-infection

►► Ambivalence about community leader

involvement

Access to knowledge and information

How can outreach and education
►► Peer education noted in both educating
strategies be improved?
about screening and encouraging treatment
►► How does peer education and support
impact treatment acquisition?
►►

Characteristics of individuals
Knowledge and beliefs about the
intervention

►►

Self-efficacy

►►

Individual stage of change

►►

Did women understand the meaning of ►► Role of HPV in development of cancer was
a positive HPV result?
well understood, however some women
►► Did women understand the process
equated an HPV-positive result with cancer
and availability of treatment?
►► Women knew that early treatment would be
simpler than treatment for advanced disease
►► Do women understand the importance
of treatment for their health?
Do women prioritise accessing
►► Women felt knowing HPV status allowed
treatment for their health?
them to move on a health action (treatment)
►► How do health beliefs and self-efficacy ►► Treatment had an empowering influence
impact women’s ability to overcome
►► Post-treatment, women felt that they could/
barriers to treatment?
should be role models
What role do peer networks or social
support play in treatment access?
►► What role do individual health beliefs
play in reactions or decisions about
treatment for a positive HPV test?

►► Women felt relief at knowing HPV status
►► Fear surrounding HPV result and association

with cancer led to some inaction

CFIR, Consolidated Framework for Implementation Research.

to discuss and make final revisions to the codebook. All
interviews were coded twice by two separate members of
the research team. Coding reports were then reviewed
collaboratively to identify important themes and finalise
mapping onto the modified CFIR framework.
Patient and public involvement
The research question and measures were informed by
preliminary work done in partnership with the Ministry
of Health to evaluate barriers and facilitators of cervical
Huchko M, et al. BMJ Open 2019;9:e028669. doi:10.1136/bmjopen-2018-028669

cancer screening and treatment. Prior to study implementation, we also carried out focus group discussions with
women living in Migori to plan and implement phase I of
the study (manuscript submitted). For this study, patients
were not involved in identification or recruitment of
participants, as all women undergoing treatment were
asked by a research assistant to participate in an interview
after their treatment had been completed. Results have
already been disseminated to the participants through
3
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Table 1 Refined CFIR constructs and key findings regarding HPV-positive women’s experiences with a referral-based
cryotherapy treatment strategy
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Results
Between February and December 2016, 5898 women
underwent cervical cancer screening in both CHC and
health facilities and 1043 (17.4%) tested positive for HPV.
Out of these women, 399 (38.3%) women presented for
treatment at Migori County Hospital and 372 (35.6%)
underwent cryotherapy. Three women were referred for
LEEP and one for invasive cancer management. Among
the 372 treated HPV-positive women, 273 women (73.4%)
completed an IDI after their treatment. The average age
for participants was 37.3 years, for 216 (79.1%) primary
school was the highest education completed, and 206
(75.4%) were married or had a current partner. There
was no difference in the clinical or demographic characteristics in the participants from the original study arm, or
between those who agreed to an interview and those who
declined. Women travelled a mean of 37 kilometres to get
to Migori for treatment, and almost all used a paid form
of transportation (bus, taxi or motorbike).
Knowledge and perceptions of HPV positivity and treatment
value
Many women expressed confidence in their level of
knowledge about the relationship between HPV and
cervical cancer, and the role of treatment in protecting
their health. Specifically, many understood that the
recommended treatment was simpler and more effective
than it would be if HPV developed into cervical cancer.
I learnt that, having HPV doesn’t mean you have the
disease, it is just a sign that it may develop in to a disease and when you have the virus and it is detected
early enough it can be treated. (Age 41 years)
Although many women were able to make fact-based
statements about HPV, and professed confidence in their
knowledge, some expressed fear, anxiety and misperceptions about their positive HPV results and the association
with cancer. This was reflected in women’s feelings around
the time they received their results and their concern that
the treatment would not ‘cure’ their cancer.
I felt pain at heart, since I do hear that those with cancer do not survive, even now I still have no assurance
of good health. (Age 43 years)
Though some women reported worry or anxiety about
their test result, many felt relief that they were now aware
of their HPV status and could get treatment.
What came into my mind after I was confirmed HPV
positive was just on how I can access treatment my
4

focus now is how I can be on treatment and that is my
key challenge as at now. (Age 47 years)
Treatment experience
Women were almost uniformly positive about provider
respect, privacy, adequate explanation of the procedure
and recovery, and ability to ask and have their questions
answered. Most women also reported minimal pain or
cramping, with no reported complications with the procedure. Overall, women expressed relief that the procedure
was not as difficult as they had feared, with responses
similar to the comment below.
When I came from home, people were saying that
this treatment is painful but I have not felt any pain. I
have found it to be good and the pain that people are
talking about is not there. (Age 36 years)
When asked how to improve the treatment experience,
women had limited suggestions, or focused on access
issues. This may not reflect satisfaction with the treatment
model as much as a feeling that it was the role of ‘healthcare providers’ or ‘doctors’ to ‘improve the experience’.
‘It is you as healthcare providers to find on ways of making it
more comfortable.’ (Age 33 years)
Unanswered questions
Despite reporting adequate explanation and overall
treatment satisfaction, a number of unanswered questions or misperceptions regarding cervical cancer or
follow-up arose throughout the interviews. When asked
whether women had unanswered questions at the end
of the screening/notification and treatment process,
they revealed underlying fears about extent of disease/
outcomes of treatment (future fertility, death from
cancer, etc). Many women were under the impression
that they would be given drugs to treat HPV, like treatment for malaria or HIV management. ‘I have learnt that
in case I will be given drugs then I will have to take them to
help prevent the virus from advancing into cervical cancer’ (Age
38 years). Women who mentioned drugs recounted that
they were told they would be given drugs, although this
was not an intended part of the health messaging during
screening or treatment.
Some women believed that if they were infected with
HPV, they would not be able to give birth, or they should
not get pregnant because the fetus would be infected with
HPV. Related to the fear of infertility, women reported
believing that family planning methods caused their positive HPV result or would cause cervical cancer. ‘I thought
that I had cervical cancer because since I went for family planning (Intrauterine Device). I have not been feeling okay in the
uterus.’ (Age 42 years)
Identifying specific barriers and facilitators to treatment
access
When women were asked whether they encountered any
barriers or difficulty accessing treatment, most answered
no. However, when prompted, many confirmed that they
Huchko M, et al. BMJ Open 2019;9:e028669. doi:10.1136/bmjopen-2018-028669
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two key stakeholder meetings. In addition, selected participants were invited to participate in a working group to
amend the treatment implementation strategy for phase
II.
All participants gave their written informed consent to
participate in the study prior to data collection. For low-literacy participants, consent was affirmed with thumbprint.

Open access

I do not know what to tell you. If you have money you
can access everywhere, but if you do not you cannot
make it on foot. The poor will die of even diseases
that can be treated unlike the rich. (Age 38 years)
When asked about how to make treatment access easier,
many women mentioned that telling their own story of
treatment to women who tested positive for HPV would
be helpful, suggesting that peer education and social
support may play a large role in the decision to get treated.
Women wanted to publicise that treatment was free, easy,
quick and important for women’s long-term health.
Examples of these sentiments include the following:
When the (positive) results came I was surprised. I
then took time and went to my friends who also were
HPV positive and shared with them, we encouraged
each other and set dates for coming for treatment.
(Age 45 years)
I would tell her it is important for her to know her
HPV status because she would be able to know if
she is at a high risk of developing cervical cancer…
Treatment is good. It is free and very easy. There is
no pain, so it is good. That is how I would encourage
her. (Age 51 years)
Women suggested two changes in the treatment model
that could facilitate treatment for women in the community: (1) A decentralised treatment model that provides
treatment in more rural health facilities, closer to homes,
or a mobile treatment unit that moves periodically
through communities. (2) Transportation provisions or
reimbursements, echoing the main barrier to treatment
access.
Finally, a substantial number of women felt that greater
awareness of or access to screening would increase uptake
of treatment. Women suggested repeating screening
in the communities for those who had missed earlier
campaigns and increasing involvement of lay health
workers, or community health volunteers, in outreach
and education around screening.
Support from peer networks and community leaders
Women wanted to share their diagnosis with others in
their community, both to be able to obtain psychological and financial support for treatment and to set an
Huchko M, et al. BMJ Open 2019;9:e028669. doi:10.1136/bmjopen-2018-028669

example. Most reported that privacy around their HPV
status was not important to them.
I am comfortable with any other person knowing my
status because, he or she might be able to support me
if am sick or I might be able to encourage and support a person who is sick but is too scared to receive
treatment.
A small minority of women who did not want to share
their diagnosis with others, apart from their spouse or
co-wives, gave reasons including a general desire for
privacy about their own health, without specific mention
of HPV or cervical cancer related stigma.
The reason why I did not want anyone else to know
is because some people tend to exaggerate things, if
one hears you have this disease, they may start telling
you how you have a very bad disease and that you will
die soon.
Women held contradictory opinions regarding the role
of community leaders in facilitating treatment. Women
who were in favour stated that leaders could ‘mobilise
women to seek treatment’ (Age 33 years), while those opposed
feared a loss of privacy, stating that ‘community leaders would
spread rumours to the community members’ (Age 37 years).
Male partner involvement
Male partner involvement was described as it related to
treatment access, post-treatment care and fears of re-infection from their partners. Almost all women interviewed
said the decision to seek treatment was theirs alone.
However, they did feel like male support or opposition
played a role in access of treatment services. Interestingly,
most women stated that while men in general would likely
not be supportive of their wives obtaining treatment,
their own spouse had been. Reasons for other husbands’
perceived lack of support were related to a lack of understanding or belief that HPV is a real threat, and low prioritisation of their wives’ health. Male support was generally
described as financial support for transportation, with a
minority naming encouragement or moral support for
treatment. Women’s comments indicate either a perception about lack of male support for other women in the
community, while descriptions of their own experience
suggest that male support was a key factor in their ability
to obtain treatment (as all the women in this group had
successfully obtained treatment).
My husband support(ed) screening so that should I
be confirmed positive, I start the treatment in time
before it worsens…he provided me with fare and
asked me to leave early so I can get to the hospital in
time. (Age 42 years)
Some do not understand cervical cancer and some
just care less about their wives and cervical cancer
hence not becoming supportive. Other men are supportive when they value the lives of their female partners. (Age 33 years)
5
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had to miss work, struggled to find childcare or transportation funds, or travelled a long distance. Some women
expressed the belief that if a woman is sick or valued her
health, there were no barriers that could stop her from
accessing treatment in statements like the following: ‘It
can only be far for someone who is not sick but if you are sick, you
cannot say that it is far. I’m here to save my life’ (Age 46 years).
Lack of access to means of transportation and/or funds
to hire transport were the main barriers that resulted in
delays in treatment. Women also worried about future
transport costs if the disease progressed, explicitly stating
that they anticipated missing future appointments.

Open access

I had a concern with the issue of not having sexual
contact with my husband for a month. We built a new
house, which we are supposed to enter into in the
course of this week. As Luos, we have our customs
that we must uphold, what will I do? (Age 35 years)
Concerns about the ability to be abstinent following
treatment were echoed in some women’s thoughts about
the futility of treatment in situations where they perceived
little control over possible reinfection. Concerns were
raised about safe relations with their husband, inability
to negotiate condoms and concerns about (re-)infection
among co-wives.
It is said that men are the one who infects us, and us
still being a young couple we are bound to have sexual relations, what can be done so to men so that they
do not spread the disease? (Age 39 years)
Supposing I have a co-wife, how will I know that she
has also been treated so that we can all be free and
not use condoms? (Age 34 years)
Treatment and empowerment
Although this group of women who were able to overcome
barriers and access treatment for their HPV likely had
higher baseline levels of empowerment than women who
did not get treatment, many women expressed a sense of
personal empowerment from the process of either undergoing treatment or from gaining an understanding of the
impact of HPV on their health. This may have been as a
key factor in overcoming barriers to treatment.
I have come to seek treatment for a better future; I
want a future so that I can continue taking care of
[my children] (Age 35 years)
Finally, almost all women said they would recommend treatment to other women who they knew tested
HPV-positive, stating that the treatment was easier than
they thought, free, quick and almost painless. Importantly, many felt that they had an important role to play
as peer educators or advocates to convince other women
who tested HPV-positive to get treatment. Often, women
expressed that their treatment experience changed their
minds about privacy and the importance of sharing their
experience.
I never felt like letting anyone know about my treatment, now that I have, I can easily encourage my
neighbour to seek for treatment in case she’s positive.
(Age 36 years)
6

I would tell her my experience about the treatment.
How easy and how painless it is. How the doctors are
prepared and how they talk nicely to us. I would tell
her she has nothing to fear and she should gather
courage and come. (Age 41 years)
Discussion
Appropriate follow-up for HPV-positive women is a critical
component in cervical cancer prevention and control;
the success of the programme in LMICs is often limited
by attrition between screening and treatment. This study
used the CFIR framework to explore the contextual
factors surrounding women’s uptake of treatment after
a positive HPV test in rural Kenya. We found that women
were generally satisfied and even empowered by their
treatment experience. The results also showed that the
belief that the treatment they were seeking would have
an important and positive impact on their health enabled
women to overcome the barriers of fear, lack of transportation funds and distance to the treatment centre. Women’s
responses were surprisingly consistent throughout the
interviews, with some level of disagreement emerging
around the importance of male involvement in their own
ability to seek treatment compared with their perception
of how it impacted other women.
These findings add substantially to a body of work that
has primarily focused on structural, financial, and policy-related barriers and facilitators to the implementation
of a cervical cancer screening and treatment programme
by exploring the patient experience from receiving
results to navigating treatment access.17 18 The participant
perspectives provide important insight into ways the treatment model can be improved. To our knowledge, this is
the only study to assess patient-level factors impacting
cryotherapy treatment in a low-resource setting using the
CFIR framework. The use of a standardised framework
is important to developing a sustainable and effective
enhanced linkage to treatment strategy with the potential
for replication in other settings.
The fact that empowerment associated with treatment
emerged so strongly was encouraging and indicated a
facilitating culture. However, substantial logistical and
financial barriers remain in place for women in this
model, despite free screening and treatment. Women
travelled an average distance of over 30 km and almost
all women required some form of hired transportation.
While the majority of women did not recall income
loss, or reported a loss of less than 1000 Kenya Shillings
(US$10), the cost of transportation represented a significant burden, even among this group of women who were
not lost to follow-up. Partner support was significant, and
most often appeared in the form of payment for transportation. While almost all women stated that the decision to seek treatment was their own, their reliance on
partners for financial support was crucial and may have
important implications for future cervical cancer prevention and treatment initiatives. The role of partner support
Huchko M, et al. BMJ Open 2019;9:e028669. doi:10.1136/bmjopen-2018-028669
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Standard counselling after cryotherapy includes abstinence for a month, and use of a condom after resumption of sexual activity for 6 months to prevent spread of
HPV or reinfection. A few women expressed concern
about cultural and social beliefs regarding sexual activity
that would prevent their husbands from supporting
them through the recovery period, or use of a condom
afterwards. Some women even requested that a health
provider speak with their husband.

Open access
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or married, which was possibly a key factor in their success
with navigating treatment. While the qualitative data
suggest partner financial support was key in reaching
treatment sites, we must identify and work with women
who were lost to follow-up to fully begin to understand
and address insurmountable barriers. In addition, as
these interviews were done by the study team in proximity
to treatment sites, there may have been some social desirability bias in responses related to treatment experience
and provider respect.

Conclusions
These data provide valuable insight on the implementation of a community-based cervical cancer screening
programme through the perspectives of HPV-positive
women who were able to access free treatment through
referral to a county government hospital. While many
women reported feelings of self-efficacy and empowerment, and were pleased with their experience deciding
and accessing treatment, they represent the minority of
patients. Despite multiple efforts to counsel women about
the importance and availability of treatment, over half of
the women who tested HPV-positive in the parent study
did not access treatment. We have identified specific
barriers and potential facilitators to treatment access that
will inform new implementation strategies and ways to
intensify efforts to reach the wider population of women
who were lost to follow-up and work with healthcare teams
to develop a linkage to treatment strategy that ensures
greater follow-up with appropriate care.
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needs to be explored among women who were not able
to obtain treatment. The frequency at which the costs of
transportation to a distant treatment site and the reliance
on partners were reported indicates a need to explore the
decentralisation of treatment with or without a mobile
treatment unit, the use of transportation vouchers or
assistance of some type that emphasised transportation.
The use of peer educators to help encourage and facilitate treatment access may also be a strategy to overcome
the logistical hurdles using an empowerment framework. While other studies have not shown educational
interventions to be as effective as other implementation
strategies for cervical cancer prevention,19 peer-led counselling has increased perceptions of screening benefits
and engagement in screening activities.20 21 Peer-to-peer
education has played a large role in the success of the
HIV programme in this region, so participants were likely
to have experience and comfort with this. Importantly,
women saw themselves as potential peer educators, using
their positive experiences with treatment to convince
other women to get treated. In this way, the self-efficacy
they displayed in obtaining treatment would be transformed into a sense of personal empowerment through
a reflection of their own success and influence on others.
These qualitative data clearly elucidated points of
clarification for the educational counselling provided
throughout the outreach, screening and treatment activities. Although the current education modules stress that
HPV is not cancer, some women continued to believe
that a positive HPV result was synonymous with having
cancer, which then caused cancer-related fear, sometimes
resulting in inaction. Educational content and the mechanisms by which women are notified of their results should
be rigorously tested to ensure clarity, as fear of cancer
or more invasive procedures may prevent women from
seeking appropriate treatment. In addition, these data
highlight a need to address the misconceptions about
family planning, infertility and the need for medication
as part of treatment both during outreach and at the time
of screening and treatment. The persistent expectation
that treatment would involve long-term medications may
reflect an interpretation of medication as synonymous
with treatment, as is the case with the more common
diseases in the area: HIV, Tuberculosis and malaria. Based
on these findings we updated the educational material
to include more precise descriptions of the cryotherapy
procedure and clarify that treatment does not require
medication.
While these data highlighted crucial information that
allows us to further understand how and why women are
able to access treatment when free treatment is offered,
there are limitations inherent to the study design. The
current study is missing the voices and experience of
women who were unable to access treatment, who were
the majority of women screened; this may contribute
to the relative homogeneity of observed themes. For
example, in this population of women who had successfully accessed treatment, almost all were in a relationship
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